YYZ Pharmatech Inc.
Robert DeWitte, Ph.D., is an accomplished entrepreneur and executive with extensive experience in the pharmaceutical and scientific research sectors. Currently serving as Co-Founder and CEO of Elarex since December 2019 and a Strategic Advisor at YYZ Pharmatech Inc. since May 2020, Robert DeWitte previously held the role of Entrepreneur In Residence at McMaster University, focusing on commercialization of inventions. Prior to these positions, Robert DeWitte was with Thermo Fisher Scientific for 15 years, culminating in the role of Vice President of Research and Development, overseeing a $53M R&D budget and managing a diverse team across multiple countries. Additional roles include leadership positions at ACD/Labs and Abbott Laboratories. Educational credentials include a Ph.D. in Chemical Physics from Harvard University and executive finance training at Harvard Business School.
This person is not in any teams
YYZ Pharmatech Inc.
YYZ Pharmatech has created enabling technologies that overcome three fundamental challenges in modern medicine: 1) Harness blood as the most data rich sample type 2) Identify low-abundance markers of disease 3) Develop ultra-sensitive assays against the most biologically significant biomolecules About YYZ Pharmatech: YYZ builds innovative technology platforms to enable new insights in modern medicine, with breakthroughs in the ultra-sensitive discovery & measurement of biomolecules. Supported by over 20 years of published research and backed by two visionary family offices, YYZ’s technology suite is powered by: DPiPSA™ for Discovery: (Database-Driven Proteome Intact Partition Statistical Analysis) Unbiased & statistically rigorous bioinformatics for next-generation discovery & stratification. ELiMSA™ for Measurement: (Enzyme Linked Mass Spectrometric Assay) Ultra-sensitive & quantitative assay technology with extensive life science applications. YYZ is the commercialization partner of the Marshall Team at Toronto Metropolitan University (formerly Ryerson University).